Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/19/15 All times are local (Market data is delayed by at least 15 minutes).

cardax inc (CDXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/30/14 - $1.21
52 Week Low
04/24/15 - $0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARDAX INC (CDXI)

Related News

No related news articles were found.

cardax inc (CDXI) Related Businessweek News

No Related Businessweek News Found

cardax inc (CDXI) Details

Cardax, Inc., a development stage life sciences company, develops consumer health and pharmaceutical technologies for products that would provide the anti-inflammatory benefits of steroids or non-steroidal anti-inflammatory drugs. It primarily focuses on astaxanthin technologies. Astaxanthin is a naturally occurring marine compound that has anti-oxidant and anti-inflammatory activity. The company is also preparing proprietary nature-identical products and related derivatives by total synthesis to provide therapies for diseases where inflammation and oxidative stress are implicated, including osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. It has a collaboration agreement with Capsugel US, LLC to develop astaxanthin products for the consumer health market. The company is based in Honolulu, Hawaii.

9 Employees
Last Reported Date: 04/13/15

cardax inc (CDXI) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $484.9K
Executive Chairman, Chairman of Nominating & ...
Total Annual Compensation: $265.0K
Vice President of Operations, Assistant Treas...
Total Annual Compensation: $201.6K
Vice President of Research
Total Annual Compensation: $195.5K
Chief Science Officer and Member of Scientifi...
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.

cardax inc (CDXI) Key Developments

Cardax, Inc. Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 01:00 PM

Cardax, Inc. Presents at SeeThruEquity Fall Microcap Investor Conference 2014, Nov-12-2014 01:00 PM. Venue: Convene Midtown East, New York, New York, United States.

Capsugel and Cardax to Collaborate on Development of Proprietary Astaxanthin Products

Capsugel and Cardax, Inc. announced a collaboration to develop unique astaxanthin products for the consumer health market. The goal of the collaboration is to commercialize proprietary formulations of nature-identical synthetic astaxanthin products with pharmaceutical-grade purity that will provide improved oral bioavailability compared with other astaxanthin products on the market. Astaxanthin is currently used as a specialized antioxidant. The astaxanthin products will be jointly developed using Capsugel's proprietary lipid multi-particulate (LMP) technology, which encapsulates dissolved or suspended active ingredients into spherical lipid matrix particles for oral dosage in capsules, sachets, suspensions or tablets. LMP technology utilizes a range of approved lipids to deliver the benefits of lipid-based formulations in multi-particulate format, including improved bioavailability, controlled release and effective taste-masking. The companies will seek a strategic partner for retail commercialization in the mass market. Specific business terms were not disclosed.

Cardax, Inc. Announces Board Appointments

Cardax, Inc. announced the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG, Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its board of directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXI:US $0.20 USD 0.00

CDXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CDXI.
View Industry Companies

Industry Analysis


Industry Average

Valuation CDXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDAX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at